logo

FDA Calendar

Share
Company Name Vertex Pharmaceuticals Inc.
Drug Name SYMDEKO (sNDA)
Event Name FDA decision on SYMDEKO for the treatment of cystic fibrosis patients with additional rare CFTR mutations
Event Date 12/30/2020
Outcome Date
Outcome
Drug Status
Rival Drugs
Market Potential
Other Approvals SYMDEKO is already approved for the treatment of cystic fibrosis (CF) in patients age 6 years and older who have two copies of the F508del mutation, or who have at least one mutation in the CF gene that is responsive to treatment with SYMDEKO
News
Return to FDA Calendar